PDCD1 and cancer: The combination of targeted therapies with immunotherapy in the form of ICIs such as programmed cell death 1 (PD-1) has led to dramatic improvements in clinical outcomes for many cancers, but the results of monotherapy, namely, in PDAC, have been rather disappointing [17].